Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyWellfleet Self-Admin Meds Policy Update | OpenPaye…
    Ask Trek AI about this page
    ModifiedWellfleetPolicy GL-004

    Self-Administered Medications

    Customize your policy alerts

    Sign up for wellfleet Policy GL-004 alerts

    Get alerted when Policy GL-004 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This payment guideline governs medical-benefit reimbursement for self-administered medications and identifies drugs covered only under the pharmacy benefit for applicable Wellfleet plans. It applies to providers submitting claims for Wellfleet enrollees, subject to plan documents, provider agreements, mandates, and other reimbursement factors.

    Policy Summary
    PayerWellfleet
    PolicySelf-Administered Medications
    Policy CodePolicy GL-004
    Change TypeModified
    Effective DateNov 1, 2025
    Next Review DateNot scheduled
    Key ActionSubmit self-administered medications on the applicable list under the pharmacy benefit rather than the medical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    The 2025 revision removed references to ISO, Axis, and True Care as plan types.

    The 2025 revision updated the self-administered medication HCPCS code list.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1-timeInitial medical-benefit exception
    11/1/2025Current version effective
    AR, NYExcluded states
    DartmouthApplicable self-funded school
    5Final medication entries

    Coverage and Reimbursement Criteria

    Pharmacy-benefit routing for self-administered medications

    Apply the following reimbursement rules to medications covered under the applicable plan documents.

    ALL of the following

    • Medication is classified as self-administered under the manufacturer's approved labeling.
    • Medication appears on Attachment 1 with Wellfleet Rx marked Y.
    • Medication is excluded from the medical benefit and must be obtained or billed through the pharmacy benefit.

    Exceptions and initial-claim handling

    Medical-benefit exceptions may apply in limited circumstances.

    ONE of

    • Self-administered drug is required as part of a hospitalization.
    • Self-administered drug is required during an emergency-room visit.
    • The claim is the initial medical-benefit claim for the member and drug, and the drug is otherwise covered.

    Subsequent medical-benefit claims

    Claims submitted after the initial exception are subject to the following rule.

    ALL of the following

    • A subsequent claim for the same self-administered drug is billed under the medical benefit after the one-time exception.
    • Deny the subsequent medical-benefit claim and require submission through the pharmacy benefit.

    Self-Administered Medication Coding

    Self-administered medication HCPCS codes: A-BHCPCSNot Covered
    J3262ACTEMRA*; Wellfleet Rx = Y
    J9216ACTIMMUNE; Wellfleet Rx = Y
    J3241ADBRY; Wellfleet Rx = Y
    C9339/J3490/J3590AIMOVIG; Wellfleet Rx = Y
    J3031AJOVY; Wellfleet Rx = Y
    J2793ARCALYST; Wellfleet Rx = Y
    J0461ATROPEN; Wellfleet Rx = Y
    J0171AUVI-Q; Wellfleet Rx = Y
    J1826/Q3027AVONEX; Wellfleet Rx = Y
    J1815BASAGLAR; Wellfleet Rx = Y
    1–10 of 14
    1/2
    Self-administered medication HCPCS codes: B-GHCPCSNot Covered
    J2354BYNFEZIA; Wellfleet Rx = Y
    J3590CABLIVI; Wellfleet Rx = Y
    J0270CAVERJECT; Wellfleet Rx = Y
    J0725CETROTIDE; Wellfleet Rx = Y
    J0717CIMZIA; Wellfleet Rx = Y
    J3247COSENTYX; Wellfleet Rx = Y
    J0584CRYSVITA; Wellfleet Rx = Y
    J3590/J7799CUTAQUIG; Wellfleet Rx = Y
    J1555CUVITRU; Wellfleet Rx = Y
    J0895DEFEROXAMINE MESYLATE*; Wellfleet Rx = Y
    1–10 of 35
    1/4
    Medication-code listingsHCPCS
    J1595Buprenorphine HCl; Glatopa; payment indicator Y
    Medication-code listingsHCPCS
    J3490Gonal-F; payment indicator Y
    J1610Glucagon Emergency Kit; Gvoke; payment indicator Y
    J0559Glucagon Emergency Kit; Haegarda; payment indicator Y
    J3590Glucagon Emergency Kit; Hemlibra; payment indicator Y
    J1815Glucagon Emergency Kit; Humalog; payment indicator Y
    J0135/J0139Humira and biosimilars; payment indicator Y
    J1815Humulin; payment indicator Y
    J1575HyQvia; payment indicator Y
    J1744Icatibant; payment indicator Y
    J2170Increlex; payment indicator Y
    1–10 of 18
    1/2
    Medication-code listingsHCPCS
    J1050Medroxyprogesterone; payment indicator Y
    S0122Menopur; payment indicator Y
    J9260Methotrexate; payment indicator Y
    J0630Miacalcin; payment indicator Y
    J0630Myalept; payment indicator Y
    J3490/C9399Myalept; payment indicator Y
    J2310Naloxone HCl; payment indicator Y
    J2310Natpara; payment indicator Y
    J3490/C9399Natpara; payment indicator Y
    J2505Neulasta; payment indicator Y
    1–10 of 17
    1/2
    Medication-code listingsmixed
    J2353Ovidrel; payment indicator Y
    J0725Ovidrel; payment indicator Y
    J2267Omvoh; payment indicator Y
    J2267Ozempic; payment indicator Y
    C9339/J3490/J3590Ozempic; payment indicator Y
    J3490/J3590Palynziq; payment indicator Y
    J2440Palynziq; payment indicator Y
    Medication-code listingsmixed
    S0148Pegasys; payment indicator Y
    J3430Phytonadione; payment indicator Y
    J1830Plegridy; payment indicator Y
    J0885Procrit; payment indicator Y
    J2675Progesterone; payment indicator Y
    J9250Rasuvo; payment indicator Y
    Q3026/Q3028Rebif; payment indicator Y
    J2212Relistor; payment indicator Y
    J3285Remodulin; payment indicator Y
    J3490Repatha; payment indicator Y
    1–10 of 23
    1/3
    Medication-code listingsmixed
    J3490SymlinPen; payment indicator Y
    J9262Synribo; payment indicator Y
    J0593Takhzyro; payment indicator Y
    J3490/C9399Taltz; payment indicator Y
    J3490Tegsedi; payment indicator Y
    J1080Testosterone cypionate; payment indicator Y
    J3121Testosterone enanthate; payment indicator Y
    J1815Toujeo Solostar; payment indicator Y
    C9029Tremfya; payment indicator Y
    J3285Treprostinil; payment indicator Y
    1–10 of 16
    1/2
    Medication-code listingsmixed
    J1558Xembify; indicator 1 = X, indicator 2 = Y
    C9399/J3490Xultophy 100-3.6; indicator 1 = X, indicator 2 = Y
    Q5101Zarxio; indicator 1 = X, indicator 2 = Y
    C9058Ziextenzo; indicator 1 = X, indicator 2 = Y
    J2941Zorbtive; indicator 1 = X, indicator 2 = Y

    Provider Billing and Documentation Actions

    Documentation Required

    Accurate Claims and Supporting Documentation

    Submit accurate claims for self-administered medications. Retain supporting provider records because Wellfleet may request documentation for submitted claims.

    Billing Rule

    Route Self-Administered Medications to the Pharmacy Benefit

    Determine whether a medication is self-administered under the manufacturer's approved labeling. When the medication is identified as self-administered and marked “Y” under the Wellfleet Rx column in Attachment 1, submit it under the pharmacy benefit rather than the medical benefit.

    • Self-administered medications generally include oral drugs, suppositories, topical medications, and other drugs that do not require clinical supervision or assistance to consume, apply, or inject.

    Key Terms

    Self-Administered Drugs or Self-Administered Medications
    Outpatient useMedications that can be used on an outpatient basis.
    Clinical assistanceGenerally do not require clinical supervision or assistance to consume, apply, or inject.
    Classification basisDetermined through review of the manufacturer's approved labeling guidelines.
    Meaning of administeredRefers only to the physical process by which the drug enters the patient's body, not whether a medical professional supervises the process or observes technique or side effects.
    Typical routesWith limited exceptions, oral drugs, suppositories, and topical medications are generally considered usually self-administered by the patient.
    Policy Summary
    PayerWellfleet
    PolicySelf-Administered Medications
    Policy CodePolicy GL-004
    Change TypeModified
    Effective DateNov 1, 2025
    Next Review DateNot scheduled
    Key ActionSubmit self-administered medications on the applicable list under the pharmacy benefit rather than the medical benefit.
    SourceLink
    On This Page
    Coverage and Reimbursement CriteriaSelf-Administered Medication CodingProvider Billing and Documentation ActionsKey Terms
  1. Members may obtain the medication through the pharmacy and bring it to the physician's office for administration training or assistance.
  2. Denial Risk

    Medical-Benefit Billing Restriction

    Do not bill self-administered drugs through a physician's office or outpatient hospital under the medical benefit, except when a stated coverage exception applies.

    • Exceptions may include emergency situations and self-administered drugs required as part of a hospitalization or emergency-room visit.
    • Drugs furnished incident to a physician service are covered under the medical benefit only when they are not usually administered by the patient.
    Denial Risk

    One-Time Initial-Claim Exception

    Wellfleet allows one initial medical-benefit claim exception per member per drug when the self-administered drug is determined to be covered. After that one-time exception, subsequent medical-benefit claims will be denied and must be submitted through the pharmacy benefit.

    • The first qualifying medical-benefit claim is paid.
    • The explanation of benefits identifies the subsequent-claim pharmacy-benefit requirement.
    Note

    Medical Necessity Review

    Support medical-necessity determinations using Wellfleet's primary criteria source, Milliman Care Guidelines (MCG). When MCG criteria are unavailable, use evidence-based, peer-reviewed journals or other physician-reviewed resources until MCG publishes standard criteria.

    Billing Rule

    Apply Listed Medication Billing Rules

    Apply the medication-specific billing rules in the current Attachment 1 when submitting claims. Use the listed HCPCS codes and the applicable Wellfleet Rx payment indicator; codes marked “Y” under Wellfleet Rx are identified as self-administered and excluded from the medical benefit under this guideline.

    • Verify the current attachment because the self-administered medication list may change as new medications become available.
    • Use the exact listed code or code combination for the medication, including applicable HCPCS codes such as J3490, J3590, C9399, J1815, J2505, J2941, J3490/C9399, and Q5101.
    • Asterisks identify medications available in intravenous formulations; do not substitute an IV formulation or code for the listed medication-specific billing rule without verifying the current attachment.
    • Examples of listed medication-specific codes include J1595 (Glatopa), J0135/J0139 (Humira and biosimilars), J3357 (Stelara and biosimilars), J1558 (Xembify), C9058 (Ziextenzo), and J2941 (Zorbtive).